VANZACAFTOR WITH TEZACAFTOR AND WITH DEUTIVACAFTOR

Brand name:

• Alyftrek®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

VERTEX PHARMACEUTICALS PTY LTD

Condition/indication:
(therapeutic use)

• Cystic fibrosis

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

New PBS listing (Matters arising/Matters outstanding)

Comment:

--

Other PBAC consideration:

• VANZACAFTOR WITH TEZACAFTOR AND WITH DEUTIVACAFTOR

Submission received for:

September 2025 PBAC meeting

Opportunity for consumer comment:

--

PBAC meeting:

Held on 05/09/2025

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

07/10/2025

Lodgement of required documentation:

16/10/2025

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 26/11/2025

Status:

Finalised

Government processes:

Commenced on 01/12/2025

Medicine listed on the PBS:

01/02/2026 (see PBS schedule)